Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New RNA drug aims to reverse liver damage in NASH patients

NCT ID NCT06322628

Disease control Sponsor: Visirna Therapeutics HK Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing an experimental drug called VSA006 in 48 Chinese adults with NASH, a type of fatty liver disease that can lead to cirrhosis. VSA006 is an RNA-based drug designed to lower a liver protein linked to disease progression. The study compares VSA006 injections every 12 weeks against a placebo, measuring improvements in liver scarring and inflammation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
VSA006 (a type of RNA drug called siRNA that targets a liver protein linked to NASH)
What this could lead to
If successful, this could lead to a new treatment that slows or reverses liver damage in people with NASH, reducing the risk of cirrhosis.
What could go wrong
This is an early phase 2 trial with only 48 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

48 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * body mass index (BMI) of 24-35 kg/m2 ; * NASH patients confirmed by liver histopathology: NAS score is ≥ 4 and CRN fibrosis is F2 or F3 ; * At screening, ALT is \> ULN; * At screening, the liver fat content measured by MRI-PDFF is ≥ 8%; * Weight change \< 5% at least 3 months prior to screening; * For patient with T2DM, the hypoglycemic agents and HbA1c is stable Exclusion Criteria: * Pregnant or lactating women; * Previous diagnosis of alcoholic liver disease or hepatitis/liver disease due to other causes; * Previous or current diagnosis of cirrhosis or decompensated cirrhosis; * Previous or current diagnosis of hyperthyroidism, hypothyroidism, or other diseases that can lead to fatty degeneration of liver; * Participants diagnosed with type 1 diabetes, or with unstable type 2 diabetes * Participants who cannot receive an MRI examination;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASH are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASH

Contacts and locations

Locations

  • Beijing Tsinghua Changgeng Hospital

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.